Interactive Session:
85. Clinical Controversies
Thursday, October 27, 2016: 2:00 PM-3:30 PM
Room: La Nouvelle Orleans Ballroom

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss the evidence in support of treatment of staphylococcal osteomyelitis with oral antibiotics alone
  • review the risk of HIV transmission to a sexual partner when the HIV viral load is undetectable due to effective ART
  • review recent evidence for the role of asymptomatic carriers of Clostridium difficile in the epidemiology of CDI

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, HIV clinicians, HIV specialists, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Trainee, Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Interactive Moderators:  Patrick Joseph, MD, FIDSA, FSHEA, University of California, San Francisco and J Trees Ritter, DO, FIDSA, Central Coast Infectious Diseases Consultants

2:00 PM
RESOLVED! Oral Antibiotics Are Appropriate Initial Therapy for Staphylococcal Osteomyelitis
Douglas Osmon, MD
Eric Senneville, MD, PhD

2:30 PM
Do HIV Viral Load Undetectable Males Need to Wear a Condom?
Lisa G. Winston, MD

Roy M. Gulick, MD, MPH, FIDSA

3:00 PM
Should All Hospital Admissions be Screened for Clostridium difficile?
L. Clifford Mcdonald, MD, FSHEA

Daniel J. Diekema, MD, FIDSA, FSHEA

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours 0.15 of pharmacy CE

ACPE Number: 0221-9999-16-239-L01-P


P. Joseph, None

J. T. Ritter, None

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.